The pioneering test, which scientists claim is 80% accurate, analyses networks of proteins in breast cancer tumours to determine a patient's best treatment options.
Research into the technology, named DyNeMo, found those who survive breast cancer have a different organisation of the network of proteins within tumour cells.
Scientists at Mount Sinai Hospital said the tests can be used to predict the outcome in a newly diagnosed breast cancer patient to assist clinicians in making informed decisions on treatment.
Ed Yong, from Cancer Research UK, said: "Not all breast cancers are the same. By working out the differences between them at a molecular level, techniques like these could allow breast cancer patients to receive more personalised treatment from their doctor, but there's still a long way to go before we get to that point."
It is hoped the tool will be available for use within the next five years and could eventually be altered to analyse other types of cancer "to deliver individualised medicine in which healthcare professionals will be able to provide more accurate and personalised diagnoses and treatments".
Related article on NursingTimes.net: